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Objective: Hypoxic exposure in healthy subjects can induce acute mountain sickness
including headache, lethargy, cerebral dysfunction, and substantial cerebral structural
alterations which, in worst case, can lead to potentially fatal high altitude cerebral
edema. Within this context, the relationships between high altitude-induced cerebral
edema, changes in cerebral perfusion, increased brain parenchyma volume, increased
intracranial pressure, and symptoms remain unclear.
Methods: In 11 subjects before and after 6 days at 4350 m, we performed
multiparametric magnetic resonance investigations including anatomical, apparent
diffusion coefficient and arterial spin labeling sequences.
Results: After the altitude stay, while subjects were asymptomatic, white matter volume
(+0.7 ± 0.4%, p = 0.005), diffusion (+1.7 ± 1.4%, p = 0.002), and cerebral blood flow
(+28 ± 38%; p = 0.036) were significantly increased while cerebrospinal fluid volume
was reduced (−1.4 ± 1.1%, p = 0.009). Optic nerve sheath diameter (used as an index
of increased intracranial pressure) was unchanged from before (5.84 ± 0.53 mm) to after
(5.92 ± 0.60 mm, p = 0.390) altitude exposure. Correlations were observed between
increases in white matter volume and diffusion (rho = 0.81, p = 0.016) and between
changes in CSF volume and changes in ONSD s (rho=−0.92, p= 0.006) and symptoms
during the altitude stay (rho = −0.67, p = 0.031).
Conclusions: These data demonstrate white matter alterations after several days at
high altitude when subjects are asymptomatic that may represent the normal brain
response to prolonged high altitude exposure.
Keywords: hypoxia, altitude, brain volume, diffusion, cerebral blood flow, intracranial pressure
INTRODUCTION
Over the past decade, several studies reported that acute normobaric hypoxic exposure (inspiratory
O2 fraction, FiO2 = 0.11–0.12) lasting for less than 1 h (Dubowitz et al., 2009; Rupp et al.,
2014) up to 22 h (Bailey et al., 2006; Kallenberg et al., 2007; Mairer et al., 2012; Lawley
et al., 2013, 2014) increases brain gray (GM) and/or white (WM) matter volumes assessed by
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magnetic resonance imaging. The underlying mechanisms and
the consequences of increased brain parenchyma volume during
acute hypoxic exposure remain unclear. It might be associated
with cerebral subedema [as suggested by changes in apparent
diffusion coefficient (ADC) and fractional anisotropy for instance
(Kallenberg et al., 2007; Schoonman et al., 2008; Mairer et al.,
2012; Lawley et al., 2013; Rupp et al., 2014)] or with increased
cerebral blood volume (Dubowitz et al., 2009; Wilson et al., 2009,
2013; Lawley et al., 2014), while its role regarding symptoms
of acute mountain sickness (AMS: headache, dizziness, fatigue,
nausea, etc) is debated. More specifically, reduced ADC during
acute hypoxic exposure might be associated with AMS symptoms
while increased ADC and reduced fractional anisotropy might be
part of the normal physiological response to hypoxia (Kallenberg
et al., 2007; Schoonman et al., 2008; Hunt et al., 2013; Lawley
et al., 2013; Rupp et al., 2014). Increased brain parenchyma
volume may be important regarding symptoms such as headache
by promoting increased intracranial pressure (Bailey et al., 2006;
Kallenberg et al., 2007; Lawley et al., 2014).
Sagoo et al. (2016) recently exposed 12 subjects to a
FiO2 = 0.12 for 22 h with serial magnetic resonance imaging
sequences. Together with symptoms of AMS, subjects showed
significant increases in GM and WM volumes and ADC and a
significant reduction in intracranial cerebrospinal fluid (CSF).
The increase in WM volume only correlated with symptoms of
AMS. These authors suggested that the development of cerebral
subedema with increased brain parenchyma volumes as well as
venous outflow restriction may induce an increase in intracranial
pressure probably responsible for symptoms Lawley et al. (2014)
explored the relationship between changes in brain volume,
magnetic resonance imaging-derived intracranial pressure, and
AMS symptoms in 13 subjects exposed to FiO2 = 0.12 for 10 h.
While total brain volume significantly increased and CSF volume
decreased for the whole group after hypoxic exposure, subjects
with AMS symptoms had a significant increase in intracranial
pressure compared to subjects without AMS. These data support
the notion that increased intracranial pressure might be a key
mechanism underlying AMS symptoms.
Optic nerve sheath diameter (ONSD) was recently studied
in healthy subjects exposed to high altitude (Fagenholz et al.,
2009; Strapazzon et al., 2014) since this parameter was correlated
with intracranial pressure value in critically ill patients (Geeraerts
et al., 2008). An enlargement of ONSD during high altitude
exposure has been reported and may be associated with
altitude-induced increase in intracranial pressure and symptoms
(Fagenholz et al., 2009; Strapazzon et al., 2014). While ONSD
was measured at high altitude by ultrasonography, magnetic
resonance imaging has been used to validate ONSD as an index of
increased intracranial pressure (Geeraerts et al., 2008; Steinborn
et al., 2011). Hence, assessing ONSD together with other
magnetic resonance imagingmeasurements of brain parenchyma
volume and subedema and cerebral perfusion should provide
useful information regarding the mechanisms of brain responses
to high altitude and the putative relationships between cerebral
subedema, changes in cerebral perfusion, increased brain
parenchyma volume, increased intracranial pressure, and AMS
symptoms.
In the present study, we aimed to assess changes in brain
volume, ADC, and ONSD following several days of high altitude
exposure, when symptoms of AMS have disappeared (as opposed
to previous studies having investigated cerebral subedema and
changes in brain volume within the first 24 h) but when increased
cerebral blood flow is still present (Villien et al., 2013). We
hypothesized that WM volume would be increased together
with increased ADC and reduced fractional anisotropy but
unchanged ONSD (since we expected intracranial pressure and
AMS symptoms to be normalized after 6 days at altitude), which
would characterize the normal brain response to prolonged
hypobaric hypoxic exposure.
SUBJECTS AND METHODS
Subjects
Eleven healthy male subjects (28± 8 years old) were recruited to
participate to this study and provided written informed consent.
Participants were recreational climbers, taking no medication,
and having no history of cardiovascular, cerebrovascular and
respiratory diseases. Their altitude of residence was <1000m
(200–900m), they were not acclimatized to high altitude (no
night above 1500m or sojourn above 2500m of altitude
over the past 3 months) and received no treatment to
prevent acute mountain sickness. The study was approved by
the local ethics committee and performed according to the
Declaration of Helsinki (registration number: RCB2011-A00071-
40, ClinicalTrials.gov ID: NCT01565603).
Experimental Design
Magnetic resonance imaging examinations including volumetric,
DWI, and arterial spin labeling sequences were performed in
Grenoble (212m) before and within 6 h after returning from
6 days at 4350m of altitude (Observatoire Vallot, Mont Blanc,
Chamonix, France). Subjects underwent helicopter transport
lasting for 10min between the valley and high altitude (4350m).
They remained for 6 days in the Observatoire Vallot, without
further ascent, and without performing any climbing or
prolonged physical activities. They kept their usual diet and
slept for at least 7 h per night. Because 11 subjects could not
be evaluated simultaneously during and immediately after the
altitude stay, the experiment was performed over 2 weeks, a
subgroup of 5 (or 6) subjects being exposed to high altitude
and investigated according to the same protocol during each
week. Data regarding arterial spin labeling have been previously
reported (Villien et al., 2013).
Magnetic Resonance Imaging Examination
Before and after the altitude stay, magnetic resonance images
were acquired using a whole body scanner at 3 Tesla (Philips
Achieva 3.0T TX, Best, Netherlands) equipped with a 32-channel
head receive array. The following sequences were applied:
(i) High resolution 3D T1-weighted MP-RAGE gradient-echo
sequence covering the whole brain: 800 ms inversion time,
linear order phase encoding, TFE factor of 55 with 2300 ms
segment repetition time, 4 ms echo time, 25ms repetition
time, 15◦ flip angle, sagittal orientation with 256mm (H-F)×
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241mm (A-P) × 160mm (L-R) field of view, 272 × 234 ×
100 nominal acquisition matrix, SENSE acceleration factors
of 2.2 in A-P and 1.6 in L-R phase encoding directions,
reconstructed to 0.89× 0.89× 1.20mm resolution;
(ii) High resolution 3D T2-weighted TSE sequence (BrainView
T2) covering the whole brain: linear order phase encoding,
half-Fourier factor of 0.8, TSE factor of 168, 233ms echo
time, 2500ms repetition time, 90◦ flip angle, axial orientation
with 256mm (A-P)× 224mm (L-R)× 224mm (H-F) field of
view, SENSE acceleration factors of 1.2 in L-R and F-H phase
encoding directions, 256 × 223 × 224 acquisition matrix
reconstructed to 1.00mm isotropic resolution.
(iii) Diffusion-weighted spin-echo single-shot echoplanar
imaging: 59 axial slices acquired in interleaved order and
distributed over two packages, 2.25mm slice-thickness,
0.25mm inter-slice gap, 220mm square field of view, 88 ×
85 nominal acquisition matrix, SENSE acceleration factor of
3 in L-R echoplanar imaging blip gradient direction, 96× 96
reconstruction to 2.29mm in plane resolution, 74ms echo
time, 2939ms repetition time between packages, 90◦ flip
angle, diffusion weighting b factor of 1000 s/mm2 applied in
6 directions. A standard gradient echo data set at two echo
times was also acquired in view of B0 field map estimation
for magnetic field susceptibility-related geometric distortion
correction;
(iv) Pseudo-continuous arterial spin labeling acquisition, as
previously described (Villien et al., 2013): WET pre-
saturation, 1650ms label, 1525ms post-label delay, multi-
slice single-shot EPI readout (3× 3× 6mm3, 20 slices, 12ms
echo time, sense-factor 2.5), repetition time of 4 s.
Standard processing of the anatomical images was performed
using SPM8 (Wellcome Department of Cognitive Neurology,
London, UK) and FSL 4.1.9 (Analysis Group, FMRIB, Oxford,
UK) softwares as described previously (Rupp et al., 2014). All
individual images were spatially normalized to images recorded
before altitude exposure. Segmentation of T1 images was
performed to obtain GM and WM volumes while segmentation
of T2 images was performed to obtain CSF volume. Data from
one subject had to be excluded due to excessive head motion.
ADC and fractional anisotropy maps were computed from
the eigenvalues of the diffusion tensor as estimated by FSL,
after correction for eddy currents and affine motion (FSL’s
“eddy_correct” tool) and masking (mask extracted from b = 0
image using FSL’s “bet” tool). These maps were then coregistered
with the corresponding T1 images. WM and GMmasks obtained
from segmentation of T1 images were used to compute individual
WM or GM ADC and fractional anisotropy maps.
Arterial spin labeling data were analyzed as previously
described (Villien et al., 2013) and changes in cerebral blood
flow from before to after altitude were converted into changes in
cerebral blood volume based on the 0.38 power-law relationship
(Grubb et al., 1974; Dubowitz et al., 2009). According to this
relationship, changes in cerebral blood volume can be estimated
from changes in cerebral blood flow based on the following
equation:
Cerebral blood volume= 0.80× Cerebral blood flow0.38
ONSD was assessed according to Geeraerts et al. (2008). Briefly,
T1-weighted magnetic resonance imaging was used to measure
ONSD in an axis perpendicular to the optic nerve, 3 mm
behind the globe using an electronic caliper (Figure 1). Three
consecutive measurements were done bilaterally by the same
experimenter (PC) blinded for experimental conditions (before-
after altitude). ONSD was not available in three subjects due to
excessive head motion and technical issue.
Symptoms and Cardiorespiratory
Parameters
Every morning at high altitude, subjects were asked to complete
self-reported questionnaires for AMS evaluation according to
the Lake Louise score (five items) (Roach et al., 1993) and
to score perceived headache on a 10-cm visual analog scale.
Cumulative Lake Louise score and perceived headache scores
were obtained by adding each individual morning score over the
6 days at high altitude. Before each magnetic resonance imaging
examination, the following cardiorespiratory parameters were
assessed: heart rate and non-invasive blood pressure (Dinamap,
GE Medical Systems Inc., Milwaukee, WI), arterial oxygen
saturation using finger-pulse oximetry and end-tidal CO2 partial
pressure (Maglife, Schiller AG, Baan, Switzerland).
Statistical Analysis
All statistical procedures were completed on Statistica version
10 (Statsoft, Tulsa, OK, USA). The Wilcoxon test was used to
compare values before and after altitude exposure. Relationships
between magnetic resonance imaging parameters were evaluated
by Spearman correlation coefficient (rho). An alpha level of 0.05
was used as the cut-off for significance. All data are presented as
mean values± SD.
RESULTS
Symptoms and Cardiorespiratory
Parameters
Lake Louise score and perceived headache increased during
the first days at high altitude with individual maximum scores
reached within the first 3 days (mean maximal Lake Louise score
6 ± 3 pts (range of individual values: 2–10 pts), mean maximal
perceived headache 57 ± 16mm (range of individual values:
32–76mm); all p < 0.05 compared to sea level) while on the
last day at high altitude (Day 6) scores were not significantly
different anymore compared to sea level (Lake Louise score 1 ±
1 pts (range of individual values: 0–3 pts), headache 13 ± 15mm
(range of individual values: 0–53mm); all p > 0.05).
Heart rate (61 ± 8 bpm before altitude vs. 63 ± 8 bpm after
altitude, p = 0.152), mean arterial blood pressure (104 ± 6
vs. 106 ± 8mmHg, p = 0.303) and arterial oxygen saturation
(97 ± 1 vs. 98 ± 1%, p = 0.198) did not differ before and
after altitude exposure while end-tidal CO2 partial pressure was
significantly lower after altitude exposure (41 ± 5 vs. 33 ±
4mmHg, p < 0.001).
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FIGURE 1 | Example of ONSD measurement on T1-weighted magnetic resonance image in a representative subject.
FIGURE 2 | Gray and white matter and cerebrospinal fluid (CSF) volumes before and after 6 days at 4350m [(A), absolute values; (B), before-after
changes]. Data points are means ± SD, boxes are 95% confidence intervals. *Significant difference between before and after (p < 0.01).
Cerebral Volumes
A significant increase in WM volume (+0.7 ± 0.4%, p = 0.005)
was observed after altitude exposure compared to before while
no significant change were observed for GM volume (Figure 2).
Total brain parenchyma volume (WM+GM) did not change
significantly (1265 ± 106ml before altitude vs. 1267 ± 107ml
after altitude, p = 0.441). CSF volume was significantly reduced
after altitude exposure (−1.4 ± 1.1%, p = 0.009; Figure 2).
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Changes in CSF volume only correlated with cumulative Lake
Louise score (Figure 3B) and perceived headache (rho = −0.93,
p < 0.001).
Diffusion
WM ADC was significantly increased after altitude exposure
(Figure 4) while no change in GM ADC was observed (854 ±
33 × 10−6mm2/s before altitude vs. 850 ± 33 × 10−6mm2/s
after altitude, p = 0.508). Similarly, WM fractional anisotropy
was significantly reduced after altitude exposure (Figure 4) while
GM fractional anisotropy did not change (208 ± 133 vs. 205 ±
130 × 10−3, p = 0.355). The increases in WM volume and WM
ADC were significantly correlated (Figure 3A).
Cerebral Blood Flow and Volume
WM (33.1 ± 8.3ml·100 g−1·min−1 before altitude vs. 40.1 ±
5.1ml·100 g−1·min−1 after altitude; p = 0.036) and GM (72.5
± 14.8 vs. 82.1 ± 10.0ml·100 g−1·min−1; p = 0.047) cerebral
blood flow significantly increased after altitude exposure. Neither
changes in cerebral blood flow nor in cerebral blood volume
(WM+2.5± 3.4ml, GM+3.4± 5.0ml) after altitude correlated
with changes in parenchyma volume, ADC and fractional
anisotropy (all p > 0.05).
ONSD
ONSD was not significantly different before and after altitude
exposure (5.84 ± 0.53mm before altitude vs. 5.92 ± 0.60mm
after altitude, p = 0.390; Figure 5), with an average increase
of 1.4 ± 0.1% after altitude exposure. Changes in ONSD
were negatively correlated with changes in CSF volume only
(Figure 3C). Although no significant correlation was observed
between changes in ONSD after altitude exposure and symptoms
during the altitude stay (correlation between ONSD changes and
cumulative Lake Louise score, rho = 0.62, p = 0.08; correlation
between ONSD changes and cumulative perceived headache,
rho = 0.66, p = 0.06), the three subjects with the largest
ONSD increase from before to after altitude exposure (individual
ONSD increases:+4.1,+10.7,+13.7%) were those reporting the
largest perceived headache during altitude exposure (individual
perceived headache: 72, 66, 76mm). The mean intra-observer
FIGURE 3 | Correlations between changes in white matter apparent diffusion coefficient (ADC) and volume (A), changes in cerebrospinal fluid (CSF)
volume and cumulative Lake Louise Score (LLS) (B), changes in CSF volume and changes on optic nerve sheath diameter (ONSD) (C) during 6 days at
4350 m.
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FIGURE 4 | White matter apparent diffusion coefficient (ADC) and
fractional anisotropy (FA) before and after 6 days at 4350m. Values in
the bars indicate difference compared to before altitude. Data points are
means ± SD. *Significant difference between before and after (p < 0.01).
FIGURE 5 | Individual and mean values of optic nerve sheath diameter
(ONSD) before and after 6 days at 4350 m.
coefficient of variation for repeated measures of ONSD before
altitude exposure was 2.5%.
DISCUSSION
The present results suggest that prolonged high altitude
exposure induces brain parenchyma changes specifically in WM
characterized by significant increases in volume and ADC,
fractional anisotropy reduction, while cerebral blood flow was
enhanced in bothWM and GM. Concomitantly, CSF volume was
significantly reduced while unchanged ONSD did not support
a significant increase in intracranial pressure at the group
level. These data demonstrate for the first time that cerebral
morphometric changes previously reported after few hours of
hypoxia are still present after a prolonged altitude exposure when
subjects become acclimatized and do no report AMS symptoms
anymore.
The significant increase in WM volume observed in all
subjects of the present study is in accordance with previous
results from our laboratory following shorter (11 h) hypoxic
exposure as well as with previous results from the literature
(Hackett et al., 1998; Schoonman et al., 2008; Zhang et al., 2012).
Conversely, other results report changes in volume or diffusion
in the GM only (Morocz et al., 2001; Lawley et al., 2014). The
reason for these discrepancies is unclear but WM may be more
sensitive to vasogenic edema because of smaller density and
therefore less resistance to invasion by fluid (Fishman, 1975;
Klatzo, 1987; Hackett et al., 1998). The concomitant increase in
WM volume and ADC and the correlation between both changes
(Figure 3A) suggest that an increase in WM extracellular water
may be associated with the increasedWM volume. The reduction
in WM fractional anisotropy further supports increased WM
extracellular water after altitude exposure.
Previous studies having investigated climbers before and
several days/weeks after a prolonged (several weeks) stay
at high altitude (>5000 m) reported reduced WM or GM
volume/density (Di Paola et al., 2008; Foster et al., 2015; Kottke
et al., 2015). Zhang et al. (2013) also reported changes in regional
GM volume (decreased GM volume in the right postcentral
gyrus and right superior temporal gyrus; increased GM volume
in the right middle frontal gyrus, right parahippocampal gyrus,
right inferior, and middle temporal gyri, bilateral inferior ventral
pons and right cerebellum crus 1) in soldiers who stayed for 2
years at high altitude (2300–4400 m). These contrasting results
compared to the present study regarding individuals staying
for prolonged duration at high altitude can be explained by
differences in the level and duration of high altitude exposure,
by the time delay between the end of the altitude exposure and
the magnetic resonance imaging examinations and by potential
changes in physical activity and nutritional behaviors at high
altitude.
The cerebral blood flow increase observed in the WM could
favor extravascular fluid shift and consequently participate to
the WM ADC and volume increase. There was however no
correlation between changes in cerebral blood flow and changes
in ADC or cerebral volume. In addition, cerebral blood flow also
increased in GM without concomitant changes in GM volume
and ADC. An increase in venous blood volume is an additional
mechanism that has been recently discussed to explain increased
cerebral volume, enhanced intracranial pressure, and finally
symptoms following prolonged hypoxic exposure (Wilson et al.,
2013; Lawley et al., 2014). An increase in venous blood volume
due to impaired venous blood drainage would enhance cerebral
blood pressure and due to the cerebral autoregulation, induce
cerebral vasoconstriction. In the present study, the enhanced
cerebral blood flow rather suggests vasodilation. In addition, no
relationship between changes in cerebral blood volume calculated
from changes in cerebral blood flow and cerebral volume was
observed. Although these results do not support a potential
role of venous volume regarding changes in brain volume and
intracranial pressure as recently suggested (Wilson et al., 2013;
Lawley et al., 2014), specific measurements of cerebral venous
volume and blood pressure would be needed to assess this potent
mechanism.
Frontiers in Physiology | www.frontiersin.org 6 September 2016 | Volume 7 | Article 393
Verges et al. The Brain at Altitude
An important specificity of the present study is that magnetic
resonance imaging measurements were performed after 6 days at
high altitude when symptoms of AMS disappeared as opposed
to previous studies of cerebral changes within the first 24 h
of hypoxic exposure. The persistence of increased WM volume
and ADC and reduced fractional anisotropy indicates these
cerebral changes are independent of AMS and may represent
normal responses to high altitude as previously observed in
asymptomatic subjects (Kallenberg et al., 2007; Hunt et al.,
2013). Alternatively, it may be suggested that these WM volume
and diffusion changes represent mechanisms responsible for
symptoms during the first hours at high altitude which persist
but have been compensated after several days at high altitude.
Hence, since no significant change in total brain volume was
observed, it can be suggested that the increase in WM volume
was buffered by the reduction in CSF volume (Figure 2). The
correlation between changes in CSF volume and cumulative Lake
Louise score (Figure 3B) may suggest that the later mechanism
was particularly required in subjects with the greatest symptoms.
As a consequence, intracranial pressuremight be unchanged after
6 days of high altitude exposure, explaining the absence of AMS
symptoms including headache, as opposed to the first hours at
altitude where increased parenchyma volume may be associated
with increased intracranial pressure and symptoms (Lawley et al.,
2014).
To evaluate potential changes in intracranial pressure during
the altitude sojourn, we measured ONSD from anatomical
magnetic resonance images as this parameter was shown to detect
increased intracranial pressure in pathological or experimental
conditions (Geeraerts et al., 2008; Steinborn et al., 2011). ONSD
can also be measured using ultrasonography and several reports
described an increase in ONSD measured by ultrasonography
during high altitude exposure (Fagenholz et al., 2009; Strapazzon
et al., 2014). Strapazzon et al. (2014) measured ONSD in healthy
lowlanders before and over 8 days at 3830 m. ONSD increased
within the first 24 h and remained enlarged until 8 days of
altitude exposure. ONSD was also significantly correlated with
Lake Louise score after 24 h of altitude exposure, i.e., the more
symptomatic subjects had the largest ONSD. In the present study,
no significant change in ONSD was observed after 6 days at 4350
m, suggesting no significant increase in intracranial pressure
at the group level. The correlation between changes in CSF
volume and changes in ONSD (Figure 3C) may suggest that
subjects with the largest increase in intracranial pressure were
those where large reduction in CSF volume were required to
buffer the brain parenchyma volume increase and consequently
the enhanced intracranial pressure. Although a tendency for
more severe symptoms in subjects with the largest increase
in ONSD was observed, no significant correlation between
symptoms during the altitude sojourn, and changes in ONSD
was observed. Nevertheless, the subjects who reported the most
severe symptoms at the beginning of the altitude stay had the
greatest increase in ONSD. Hence, we cannot exclude that an
increase in ONSD which remains after several day of altitude
exposure as observed in some subjects in the present study and
in the study by Strapazzon et al. (2014) might reflect a significant
increase in intracranial pressure within the first hours at high
altitude which led to symptoms such as headache. Although
intracranial hypertension and symptoms would have resorbed
after several days at high altitude, ONSD would remain elevated
as a consequence of the transient increase in intracranial pressure
at the beginning of the altitude exposure. More studies are
required to determine the pathophysiological significance and
clinical relevance of ONSD measurements in the context of high
altitude exposure (Lochner et al., 2015).
Several limitations of the present study should be
acknowledged. The main limitation of the present study
and most previous studies of brain alterations at altitude is the
small sample size. By using helicopter transportation and a 6-day
sojourn within a relatively comfortable location (Observatoire
Vallot, Mont Blanc, Chamonix, France) and without prolonged
physical effort, the present study minimized several confounding
factors associated with high altitude exposure, and therefore
increased the ability to detect high-altitude hypoxia-induced
cerebral changes. While most previous magnetic resonance
imaging studies investigated cerebral changes induced by
normobaric hypoxia (i.e., by reducing FiO2 at sea level), the
present study assessed the effect of hypobaric hypoxia. Although
the present data have the advantage to be directly applicable
to high altitude exposure, comparisons with previous data
collected in normobaric hypoxia may be influenced by potential
differences between normobaric and hypobaric hypoxic
responses (Coppel et al., 2015; Ribon et al., 2016). Magnetic
resonance imaging measurements after altitude exposure
were performed in normoxia at sea level, i.e., while subjects
recovered normal arterial oxygen saturation. Since the time delay
between the end of high altitude exposure and the magnetic
resonance imaging measurements was less than 6 h, we believed
that most cerebral changes induced by high-altitude hypoxia
persisted when magnetic resonance imaging investigations
were conducted, although further studies are needed to clarify
the recovery of high-altitude-induced cerebral changes. Also,
compared to before altitude exposure, subjects were hypocapnic
after altitude exposure due to altitude-induced hyperventilation.
After several days at altitude however, the initial increase
in cerebrospinal pH is thought to be partly compensated
(Brugniaux et al., 2007) and it can therefore be expected that
cerebral changes observed in the present study after altitude
exposure were independent of cerebrospinal pH changes. Finally,
measurements of regional cerebral morphometric changes
are required to define regions potentially more susceptible to
hypoxic exposure.
By investigating cerebral changes with multiparametric
magnetic resonance imaging after several days of high
altitude exposure, the present study demonstrated significant
cerebral morphometric changes in subjects not reporting
AMS symptoms anymore. Hence, increased WM volume and
diffusion (indicating vasogenic subedema) as well as reduced
CSF volume and unchanged ONSD (suggesting no intracranial
hypertension) may represent the normal brain response to
high-altitude hypoxia. AMS symptoms reported over the first
hours at high altitude may nevertheless be induced by some of
these mechanisms which might be compensated later on with
acclimatization. Further multiparametric magnetic resonance
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imaging investigations are required to clarify the kinetic of brain
structural alterations and interindividual differences regarding
symptoms during acute and prolonged high altitude exposure.
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